- Home
- GLRE vs MRVI Comparison
GLRE vs MRVI Comparison
Compare GLRE & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GLRE | MRVI |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 481.5M | 559.0M |
| IPO Year | 2007 | 2020 |
Fundamental Metrics
Financial Performance| Metric | GLRE | MRVI |
|---|---|---|
| Price | $16.33 | $4.37 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.13 |
| AVG Volume (30 Days) | 169.7K | ★ 2.5M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.00 | 14.29 |
| EPS | ★ 1.05 | N/A |
| Revenue | ★ $729,777,000.00 | $185,743,000.00 |
| Revenue This Year | N/A | $12.54 |
| Revenue Next Year | N/A | $7.87 |
| P/E Ratio | $15.96 | ★ N/A |
| Revenue Growth | ★ 4.85 | N/A |
| 52 Week Low | $11.57 | $1.99 |
| 52 Week High | $19.39 | $5.00 |
Technical Indicators
Market Signals| Indicator | GLRE | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 30.58 | 59.35 |
| Support Level | $13.77 | $3.17 |
| Resistance Level | $17.02 | $5.00 |
| Average True Range (ATR) | 0.50 | 0.27 |
| MACD | -0.16 | -0.02 |
| Stochastic Oscillator | 2.17 | 50.20 |
Price Performance
Historical ComparisonAbout GLRE Greenlight Capital Re Ltd.
Greenlight Capital Re Ltd offers property and casualty reinsurance. Its customers are property and casualty insurers, and Greenlight takes on some of their risk in exchange for insurance premiums. It operates through one operating segment: property and casualty reinsurance. It generates revenue through premiums from reinsurance on property and casualty business assumed and income from investments.
About MRVI Maravai LifeSciences Holdings Inc.
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.